血源性乙型肝炎疫苗已由北京医学院附属人民医院陶其敏副教授等七人研制成功。它将为人工合成HBsAg制备多肽疫苗或遗传工程疫苗作好过渡,并及早在乙型肝炎的预防方面发挥其应有的作用。最近,本刊记者在北京走访了陶其敏同志,承其就这方面的情况以及发展前景作了介绍。 Hematogenous hepatitis B vaccine has been successfully developed by seven people, including Associate Professor Tao Qimin, Affiliated People’s Hospital of Beijing Medical College. It will make the transition to synthetic peptide vaccine or genetic engineering vaccine for HBsAg production and play its due role in the prevention of hepatitis B as early as possible. Recently, our correspondents visited Comrade Tao Qimin in Beijing and introduced their situation and development prospects in this regard.